Brooks Laboratories Limited reported a 90.2% rise in standalone net profit to ₹580.50 lakh for the financial year ended March 31, 2026. The company's revenue from operations for the year increased to ₹8,690.89 lakh from ₹8,343.99 lakh in the previous year. The consolidated financial results also showed a strong turnaround, with a net profit of ₹2,458.35 lakh compared to a loss of ₹996.70 lakh in FY25.

The Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 29, 2026. The results were submitted to the exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The Statutory Auditors, DMKH & Co., expressed an unmodified opinion on the financial results.

For the quarter ended March 31, 2026, the standalone net profit stood at ₹61.43 lakh, while revenue from operations was ₹2,064.78 lakh. On a consolidated basis, the net profit for the quarter was ₹152.30 lakh, with revenue from operations matching the standalone figure at ₹2,064.78 lakh. The company reported earnings per share (EPS) of ₹1.97 on a standalone basis for the full year.

Financial Performance Summary

The following table outlines the key financial metrics for Brooks Laboratories Limited for the quarter and year ended March 31, 2026:

The complete financial results are available on the company's website and the websites of BSE Limited and National Stock Exchange of India Ltd.

Brooks Laboratories has appointed Mr. Prashant Rathi as its Chief Executive Officer, effective June 1, 2026. He will serve in the new role in addition to his existing position as Chief Financial Officer. The decision was taken by the Board of Directors following a recommendation from the Nomination and Remuneration Committee.

Mr. Rathi is a qualified Chartered Accountant, Company Secretary, and holds a Diploma in IFRS from ACCA, UK. He brings over 13 years of experience in accounting, finance, and financial management. He has been associated with Brooks Laboratories for more than five years.

Details of Appointment

The company disclosed the appointment details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure references SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

During his tenure, Mr. Rathi has developed an understanding of the company's business operations, financial systems, and internal processes. The company stated that his expertise and familiarity with its affairs position him to contribute effectively towards future growth and long-term objectives.